secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2022-03-02T23:59:59+00:00
Accession:  0000950170-22-002622
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium appoints Dr. Barbara Troupin, former Myokardia SVP, to Board
----------------------------------------------------------------------

- Appointed Dr. Barbara Troupin, M.D., as a class I director, effective February 24, 2022.
- Will serve on the Nominating and Corporate Governance Committee.
- Dr. Troupin was most recently SVP at Myokardia; prior CMO at ERX Pharmaceuticals, Aquinox, Apricus Biosciences.
- Chairman cited her experience as Equillium prepares to initiate Phase 3 study in aGVHD and expand programs with Bioniz assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000095017022002622/0000950170-22-002622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000095017022002622/eq-20220224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer